Islet Transplantation for Chronic Pancreatitis and Donislecel-jujn for Type 1 Diabetes

Autologous pancreas islet transplantation may be considered medically necessary as an adjunct to a total or near-total pancreatectomy in individuals with chronic pancreatitis.

Allogeneic islet transplantation using an FDA-approved cellular therapy product (donislecel-jujn [ie, Lantidra]) is considered investigational for the treatment of type 1 diabetes.

Islet transplantation with donislecel-jujn is considered investigational in all other situations.